Article

Voyant Biotherapeutics, Allergan sign R&D agreement

The John A. Moran Eye Center at the University of Utah announced that Voyant Biotherapeutics-a company formed out of its Center for Translational Medicine (CTM)-has signed an exclusive research and development collaboration agreement with Allergan.

 

Salt Lake City-The John A. Moran Eye Center at the University of Utah announced that Voyant Biotherapeutics-a company formed out of its Center for Translational Medicine (CTM)-has signed an exclusive research and development collaboration agreement with Allergan.

Under the agreement-which provides for a combination of upfront, research, and milestone payments-the two companies will work together to identify disease-associated pathways and targets for the development of new therapeutic agents to treat ocular diseases. A primary effort of this collaboration will be centered on new treatments for age-related macular degeneration (AMD).

“We are extremely excited about the significance of this collaboration,” said Randall Olson, MD, chief executive officer of the Moran Eye Center. “This collaboration could not have happened without the generous contributions of hundreds of people supporting the CTM in its quest to find new treatments for the prevention and treatment of AMD and other ocular diseases.”

“We look forward to a productive collaboration with Voyant to identify and develop novel therapies for retinal disease,” said Scott Whitcup, MD, chief scientific officer and executive vice president of research and development at Allergan. “This agreement highlights Allergan’s commitment to academic and corporate partnerships to increase long-term innovation.”

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.